17
GASTROINTESTINAL DISORDERS
Clinical Effectiveness* Gastricumeel was significantly better than PPIs in compliance
and tolerability2
Compliance
20
40
60
100
%
80
** P-value: p=0,0017 in favor of Gastricumeel
very good good moderate not assessablepoor
PPIs (n=183)
Gastricumeel (n=434)
Tolerability
20
40
60
100
%
80
** P-value: p=0,0017 in favor of Gastricumeel
very good good moderate not assessablepoor
PPIs (n=191)
Gastricumeel (n=441)
* Patients with dyspepsia (suspected new or recurring acute or chronic gastritis) or heartburn
Assessment of treatment compliance and tolerability at the end of the observation period
References 2) Van Haselen, R., Cesnulevicius, K. Treatment of Dyspepsia, Heartburn, and Related Symptoms with Gastricumeel Compared to Proton Pump Inhibitors: A Prospective
Reference-Controlled Observational Study. Complement Med Res (2020): DOI: 10.1159/000511285. Online link: https://www.karger.com/Article/Fulltext/511285
